AI Article Synopsis
- - Cold agglutinin-mediated autoimmune hemolytic anemia occurs when autoantibodies cause red blood cells to clump together at cold temperatures, leading to decreased red blood cell counts.
- - There are two types: primary cold agglutinin disease, which is idiopathic, and secondary cold agglutinin syndrome (CAS), often linked to other health issues like infections, autoimmune diseases, and low-grade lymphomas.
- - The article presents a case of CAS related to diffuse large B cell lymphoma, highlighting the challenges of treatment due to anemia caused by chemotherapy, and discusses potential future therapies like novel complement inhibitors.
Article Abstract
Cold agglutinin-mediated autoimmune haemolytic anaemia is associated with the development of autoantibodies that can agglutinate red blood cells at cold temperatures. While primary cold agglutinin disease is an idiopathic lymphoproliferative disorder, secondary cold agglutinin syndrome (CAS) complicates other diseases such as infections, autoimmune diseases and cancers, mostly low-grade lymphomas. Early recognition, treatment of CAS and treatment of its associated underlying diseases are crucial to a successful outcome. We report a case of CAS in a setting of diffuse large B cell lymphoma, in which the treatment course was complicated by worsened anaemia due to chemotherapy-induced myelosuppression. We reviewed previously reported cases and discussed diagnosis and treatment strategies, including novel complement inhibitors, as potential future therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047696 | PMC |
| http://dx.doi.org/10.1136/bcr-2017-222064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!